Market Spotlight: Small-Cell Lung Cancer (SCLC)
Market Spotlight: Small-Cell Lung Cancer (SCLC)
$1,318.00
This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, licensing and acquisition deals, and drug-specific revenue forecasts.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the small cell lung cancer market, comprising key pipeline and marketed drugs, recent events and analyst opinion, probability of success, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, licensing and acquisition deals, and drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2017, there were 310,300 incident cases of small cell lung cancer (SCLC) worldwide, and forecasts that number to increase to 339,500 incident cases by 2026.
- Northern America is estimated to have the highest disease incidence (10.43 per 100,000 people), while Africa has the lowest incidence (0.47 per 100,000 people).
- Celgene’s Amrubicin, Novartis’s Hycamtin (topotecan), Aeterna’s Lobaplatin, and Bristol-Myers Squibb’s Opdivo (nivolumab) are the only marketed drugs for SCLC. These drugs are administered via the oral or intravenous routes.
- The majority of industry-sponsored drugs in active clinical development for SCLC are in Phase II, with only one drug in the NDA/BLA phase.
- Therapies in mid-to-late-stage development for SCLC focus on a wide variety of targets. The majority of the drugs in mid-to-latestage development are administered via the intravenous route, with the remainder being oral, intratumoral, intramuscular, or subcutaneous formulations.
- High-impact upcoming events for drugs in the SCLC space comprise topline Phase I/II, Phase II/III, and Phase III trial results, and an FDA decision on an sBLA.
- The overall likelihood of approval of a Phase I solid tumor asset is 5.7%, and the average probability a drug advances from Phase III is 39.4%. Drugs, on average, take 9.5 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
- There have been 10 licensing and asset acquisition activities involving SCLC drugs during 2014–19. The license agreement made in 2017 between CytRx and NantCell for the exclusive rights to develop and market aldoxorubicin for $356m was the largest deal during the period.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for SCLC have been in the early and mid-phases of development, with 89% of trials in Phase I–II, and only 11% in Phase III–IV.
- The US has a substantial lead in the number of SCLC clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the SCLC space is dominated by completed trials. GlaxoSmithKline and Pfizer have the highest number of completed clinical trials for SCLC, with 43 and 41 trials, respectively.
- Pfizer leads the industry sponsors with the highest number of clinical trials for SCLC, followed by GlaxoSmithKline.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
9 TREATMENT
9 Chemotherapy
9 Radiotherapy
9 Surgery
9 Palliative procedures
11 EPIDEMIOLOGY
15 MARKETED DRUGS
17 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Rova-T for SCLC (December 5, 2018)
27 Opdivo for SCLC (November 26, 2018)
28 Trilaciclib for SCLC (November 26, 2018)
30 Trilaciclib for SCLC (October 21, 2018)
32 Opdivo for SCLC (October 12, 2018)
34 Tecentriq for SCLC (September 25, 2018)
35 Opdivo for SCLC (August 16, 2018)
36 Tecentriq for SCLC (June 25, 2018)
38 Rova-T for SCLC (March 22, 2018)
40 Trilaciclib for SCLC (March 5, 2018)
43 KEY UPCOMING EVENTS
44 KEY REGULATORY EVENTS
44 Tecentriq’s SCLC Success Takes Edge Off Roche’s IO Position
44 Bristol’s Opdivo Enjoys IO First-Mover Advantage In SCLC
45 PROBABILITY OF SUCCESS
46 LICENSING AND ASSET ACQUISITION DEALS
47 PARENT PATENTS
48 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
54 BIBLIOGRAPHY
54 Prescription information
55 APPENDIX
LIST OF FIGURES
13 Figure 1: Trends in incident cases of SCLC, 2017–26
17 Figure 2: Overview of pipeline drugs for SCLC in the US
17 Figure 3: Pipeline drugs for SCLC, by company
18 Figure 4: Pipeline drugs for SCLC, by drug type
18 Figure 5: Pipeline drugs for SCLC, by classification
28 Figure 6: Opdivo for SCLC (November 26, 2018): Phase III – CheckMate-451
30 Figure 7: Trilaciclib for SCLC (November 26, 2018): Phase II – w/Tecentriq+Chemotherapy
32 Figure 8: Trilaciclib for SCLC (October 21, 2018): Phase Ib/IIa – w/Etoposide/Carboplatin (02)
34 Figure 9: Opdivo for SCLC (October 12, 2018): Phase III – CheckMate 331
35 Figure 10: Tecentriq for SCLC (September 25, 2018): Phase III – IMpower133 (Carboplatin + Etoposide, ES-SCLC)
38 Figure 11: Tecentriq for SCLC (June 25, 2018): Phase III – IMpower133 (Carboplatin + Etoposide, ES-SCLC)
40 Figure 12: Rova-T for SCLC (March 22, 2018): Phase II – TRINITY
42 Figure 13: Trilaciclib for SCLC (March 5, 2018): Phase Ib/IIa – w/Etoposide/Carboplatin (02)
43 Figure 14: Key upcoming events in SCLC
45 Figure 15: Probability of success in the SCLC pipeline
46 Figure 16: Licensing and asset acquisition deals in SCLC, 2014–19
47 Figure 17: Parent patents in SCLC
49 Figure 18: Clinical trials in SCLC
49 Figure 19: Top 10 drugs for clinical trials in SCLC
50 Figure 20: Top 10 companies for clinical trials in SCLC
50 Figure 21: Trial locations in SCLC
51 Figure 22: SCLC trials status
52 Figure 23: SCLC trial sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of SCLC, 2017–26
14 Table 2: Incidence rates of SCLC, 2017–26
16 Table 3: Marketed drugs for SCLC
19 Table 4: Pipeline drugs for SCLC in the US
26 Table 5: Rova-T for SCLC (December 5, 2018)
27 Table 6: Opdivo for SCLC (November 26, 2018)
29 Table 7: Trilaciclib for SCLC (November 26, 2018)
31 Table 8: Trilaciclib for SCLC (October 21, 2018)
33 Table 9: Opdivo for SCLC (October 12, 2018)
34 Table 10: Tecentriq for SCLC (September 25, 2018)
36 Table 11: Opdivo for SCLC (August 16, 2018)
37 Table 12: Tecentriq for SCLC (June 25, 2018)
39 Table 13: Rova-T for SCLC (March 22, 2018)
41 Table 14: Trilaciclib for SCLC (March 5, 2018)
48 Table 15: Historical global sales, by drug ($m), 2013–17
48 Table 16: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the